Catalyst

Slingshot members are tracking this event:

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TKPYY

100%

Additional Information

Management Comment
“The initiation of Phase 3 trials for our dengue vaccine candidate is a critical milestone, bringing us closer to delivering a vaccine that can address important unmet needs in dengue prevention. This is a significant achievement for Takeda’s vaccine program and underscores our ongoing commitment to addressing critical global health threats,”said Rajeev Venkayya, MD, President of the Global Vaccine Business Unit at Takeda. “The progress of our dengue program, along with other recent achievements, such as Phase 2b field trial initiation for our norovirus vaccine candidate and our partnership with the Bill & Melinda Gates Foundation to develop a Sabin-strain inactivated poliovirus vaccine (sIPV) exemplify how we are researching, developing and providing vaccines to protect populations in need, wherever they may reside.”

https://www.takeda.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tides, Dengue Vaccine, Tak-003, Tetravalent Immunization